Title: Effect of rosiglitazone on serum glucose, lipid and blood pressure in patients with type 2 diabetes mellitus
Abstract: AIM: To evaluate the effects of rosiglitazone therapy on serum glucose, lipid, blood pressure and insulin resistance in patients with type 2 diabetes mellitus. METHODS: Fifty-nine patients with type 2 diabetes mellitus were divided into treatment group (n=30, age (68±s 10) a) and control group (n=29, age (66±10)a). All patients were male. Based on original treatment, rosiglitazone was administrated in the treatment group and metformin for the control group. The period of treatment was 16 wk for each of both groups. The levels of serum glucose, lipid, insulin and blood pressure were measured before and after the treatment. RESULTS: After treatment, the levels of blood glucose and glycosylated hemoglobin were both decreased (P0.01). The insulin resistance was improved in both groups, but rosiglitazone group was superior to metformin's (P0.01). In treatment group, the high density lopoprotein cholesterol increased (0.1±0.3) mmol·L~(-1) ((P0.05)) and the blood pressure decreased. CONCLUSION: Rosiglitazone is effective in decreasing serum glucose and blood pressure, improving insulin sensitivity and down regulating blood lipid. It may be has potential benefit for metabolic and cardiovascular diseases.
Publication Year: 2004
Publication Date: 2004-01-01
Language: en
Type: article
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot